Tenecteplase Before Thrombectomy Extends Stroke

What Is Tenecteplase and Why Does It Matter for Stroke?

Tenecteplase is a fibrinolytic agent originally developed for myocardial infarction that has increasingly been studied and adopted for acute ischemic stroke. Compared to alteplase, the long-standing standard thrombolytic, tenecteplase has greater fibrin specificity and a longer half-life, allowing administration as a single intravenous bolus rather than a continuous infusion. This operational simplicity is particularly valuable in stroke systems of care, where every minute of delay translates into lost neurons.

For decades, intravenous thrombolysis was restricted to patients within 4.5 hours of symptom onset, based on the original alteplase trials. Beyond this window, patients faced a higher risk of intracerebral hemorrhage with relatively diminishing benefit. Endovascular thrombectomy later transformed care for large vessel occlusion strokes, with trials such as DAWN and DEFUSE 3 establishing benefit out to 24 hours in carefully selected patients with salvageable brain tissue on advanced imaging.

How Could Pre-Thrombectomy Tenecteplase Improve Outcomes in the Extended Window?

The clinical rationale for combining intravenous thrombolysis with endovascular thrombectomy rests on complementary mechanisms. Mechanical thrombectomy excels at retrieving large, proximal clots in major arteries, but small distal emboli can break off during the procedure and lodge in vessels too small to reach with a stent retriever. A pharmacologic agent like tenecteplase circulating in the bloodstream may dissolve these distal clots and improve overall reperfusion of the affected territory.

Until recently, this combined strategy had only been validated within the 4.5-hour window. The newly reported trial extends the question into the 4.5 to 24-hour late window, where patients are typically selected based on advanced imaging showing a mismatch between the small core of irreversibly damaged tissue and a larger surrounding penumbra of salvageable brain. If pre-thrombectomy tenecteplase improves functional outcomes without unacceptable bleeding risk in these patients, it could reshape stroke protocols globally and broaden access to effective treatment for patients who arrive late, including wake-up strokes.

What Are the Risks and Practical Considerations?

All thrombolytics carry a risk of bleeding, most seriously symptomatic intracerebral hemorrhage. In the standard 4.5-hour window, this risk is roughly 2 to 6 percent depending on patient characteristics. Extending thrombolysis into later windows raises legitimate safety questions, particularly for patients with extensive early ischemic changes on imaging or uncontrolled hypertension. Modern trials use advanced imaging — CT perfusion or MRI — to identify patients with viable penumbral tissue and limit selection to those most likely to benefit.

From a systems-of-care perspective, adopting late-window tenecteplase requires hospitals to have robust imaging pathways, neurointerventional capability, and rapid decision-making protocols. Patients still benefit most when treated as early as possible; the extended window is a rescue opportunity for those who could not be reached sooner, not a license to delay. Stroke organizations including the American Heart Association and European Stroke Organisation continue to update guidelines as new evidence emerges, and clinicians should expect protocols to evolve as data from this and similar trials are integrated.